Bone Biologics Company Insiders
| BBLGW Stock | USD 27.80 0.00 0.00% |
Bone Biologics employs about 2 people. The company is managed by 3 executives with a total tenure of roughly 5 years, averaging almost 1.0 years of service per executive, having 0.67 employees per reported executive. Recap of Bone Biologics' management performance can provide insight into the venture performance.
Bone |
Bone Biologics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Bone Biologics' future performance. Based on our forecasts, it is anticipated that Bone will maintain a workforce of slightly above 3 employees by January 2025.Bone Biologics Management Team Effectiveness
The company has return on total asset (ROA) of (0.5725) % which means that it has lost $0.5725 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1903) %, meaning that it generated substantial loss on money invested by shareholders. Bone Biologics' management efficiency ratios could be used to measure how well Bone Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.51 in 2024. Return On Capital Employed is likely to climb to -3.08 in 2024. At this time, Bone Biologics' Other Current Assets are fairly stable compared to the past year. Other Assets is likely to climb to 1,155 in 2024, whereas Total Current Assets are likely to drop slightly above 2.3 M in 2024.Common Stock Shares Outstanding is likely to drop to about 250 K in 2024
Bone Biologics Workforce Comparison
Bone Biologics Corp is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 157. Bone Biologics claims roughly 2.0 in number of employees contributing just under 2% to equities under Health Care industry.
Bone Biologics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bone Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bone Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bone Biologics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-03-01 | 3.5 | 7 | 2 | 499,004 | 533,948 |
| 2021-12-01 | 1.5 | 6 | 4 | 6,890,001 | 10,466,012 |
| 2017-09-01 | 1.0 | 2 | 2 | 2,026,779 | 1,826,779 |
| 2016-09-01 | 2.0 | 2 | 1 | 43,359 | 5,000 |
| 2016-06-01 | 2.0 | 2 | 1 | 807,435 | 915,614 |
| 2015-12-01 | 2.4444 | 22 | 9 | 9,139,926 | 2,220,420 |
| 2015-09-01 | 1.0 | 9 | 9 | 5,187,776 | 2,481,191 |
| 2014-12-01 | 0.3333 | 1 | 3 | 174,918 | 174,918 |
| 2014-09-01 | 0.125 | 2 | 16 | 1,119,318 | 1,825,000 |
| 2008-09-01 | 0.5 | 1 | 2 | 5,000,000 | 5,000,000 |
Bone Biologics Notable Stakeholders
A Bone Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bone Biologics often face trade-offs trying to please all of them. Bone Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bone Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Shunichi Kuroda | CoFounder Board | Profile | |
| Jeffrey Frelick | CEO President | Profile | |
| Deina Walsh | Chief Officer | Profile |
About Bone Biologics Management Performance
The success or failure of an entity such as Bone Biologics Corp often depends on how effective the management is. Bone Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bone management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bone management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.39) | (2.51) | |
| Return On Capital Employed | (3.24) | (3.08) | |
| Return On Assets | (2.39) | (2.51) | |
| Return On Equity | (3.08) | (2.93) |
Please note, the imprecision that can be found in Bone Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bone Biologics Corp. Check Bone Biologics' Beneish M Score to see the likelihood of Bone Biologics' management manipulating its earnings.
Bone Biologics Workforce Analysis
Traditionally, organizations such as Bone Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bone Biologics within its industry.Bone Biologics Manpower Efficiency
Return on Bone Biologics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 4.5M | |
| Net Loss Per Executive | 3M | |
| Working Capital Per Employee | 1.5M | |
| Working Capital Per Executive | 968.8K |
Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.